Saturday, October 22, 2022, 7:30 AM – 5:30 PM Eastern Time

The Clinical Implications of Key Recent Data Sets in Oncology: A Daylong Multitumor Educational Symposium in Partnership with Florida Cancer Specialists

A CME/MOC- and NCPD-Accredited Event

Location
JW Marriott Orlando, Grande Lakes
4040 Central Florida Parkway
Orlando, FL 32837
Hotel Phone: (407) 206-2300

Program Schedule — Eastern Time
7:30 AM – 5:30 PM
Breakfast and lunch buffet to be provided

Meeting Room
Coquina Ballroom – Lobby Level


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. However, preregistration is advised as seating is limited for the in-person meeting in Orlando. See LOCATION tab for instructions on how to secure hotel accommodations.  
 
Faculty Presenting in Person

Lung Cancer

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Christine M Lovly, MD, PhD
Associate Professor of Medicine
Division of Hematology and Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Program
Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Chronic Lymphocytic Leukemia and Lymphomas

Ann S LaCasce, MD, MMSc
Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
Associate Professor of Medicine
Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Mitchell R Smith, MD, PhD
Clinical Professor of Medicine
George Washington University
Washington, DC
Chief Medical Officer
The Follicular Lymphoma Foundation
London, United Kingdom

Prostate and Bladder Cancers

Alicia K Morgans, MD, MPH
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Evan Y Yu, MD
Professor of Medicine
Division of Oncology, Department of Medicine
University of Washington School of Medicine
Member, Clinical Research Division
Fred Hutchinson Cancer Center
Medical Director, Clinical Research Services
Fred Hutchinson Cancer Research Consortium
Seattle, Washington

Breast Cancer

Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Director, Mayo Clinic Breast Cancer SPORE
Mayo Clinic
Rochester, Minnesota

Ian E Krop, MD, PhD
Associate Director, Clinical Research
Director, Clinical Trials Office
Chief Clinical Research Officer
Yale Cancer Center
New Haven, Connecticut


Gastrointestinal Cancers

Wells A Messersmith, MD
Chief Medical Officer, Cancer Center
Associate Director of Clinical Services
University of Colorado Cancer Center
Aurora, Colorado

John Strickler, MD
Associate Professor
Duke University
Durham, North Carolina

Faculty Presenting Virtually

Renal Cell Carcinoma

Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom

CAR-T and Bispecific Therapy for Multiple Myeloma

Saad Zafar Usmani, MD, MBA
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Hepatobiliary Cancers

Ghassan Abou-Alfa, MD, MBA
Attending
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College at Cornell University
New York, New York

Endometrial Cancer

Shannon N Westin, MD, MPH
Professor
Director, Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Ovarian Cancer and PARP Inhibitors

David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
The Ohio State University and The James Cancer Center
Columbus, Ohio

Melanoma

Prof Georgina Long, AO, BSc, PhD, MBBS
Co-Medical Director
Professor of Medical Oncology and Translational Research
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia

Moderator Hosting in Person
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from ADC Therapeutics, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Merck, Natera Inc, Novartis, Regeneron Pharmaceuticals Inc, and Seagen Inc.

Join us on Saturday, October 22nd for this daylong multitumor CME-MOC/NCPD-accredited hybrid event.
7:30 AM – 5:30 PM Eastern Time

Registration and Breakfast Buffet | 6:45 AM –7:30 AM ET

Module 1
Lung Cancer | 7:30 AM – 8:30 AM ET

  • Patient selection for and appropriate incorporation into routine practice of adjuvant osimertinib in light of findings from the Phase III ADAURA trial
  • Available data with and ongoing evaluation of patritumab deruxtecan for metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibition
  • Activity and tolerability of amivantamab and lazertinib in the CHRYSALIS-2 trial for patients with NSCLC with EGFR mutation after disease progression on osimertinib and platinum-based chemotherapy
  • Key efficacy and safety data informing the FDA approvals of mobocertinib and amivantamab for patients with EGFR exon 20 insertion mutations and disease progression on first-line chemotherapy
  • Factors in the selection among novel ALK inhibitors (eg, alectinib, brigatinib, lorlatinib) as first-line therapy for patients with NSCLC with ALK rearrangements
  • Efficacy and safety of entrectinib for ROS1-positive NSCLC; appropriate integration into practice
  • Available data with, FDA breakthrough therapy designation for and ongoing evaluation of repotrectinib for NSCLC with ROS1 rearrangement
  • Key efficacy and safety outcomes from the Phase II DESTINY-Lung01 study evaluating trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutation or overexpression
  • Emerging results from the Phase III DESTINY-Lung02 study and the recent FDA approval of T-DXd for NSCLC with HER2 mutation
  • Findings from the Phase II CRESTONE trial assessing seribantumab for advanced solid tumors with NRG1 fusions, including NSCLC
  • Emerging data from the Phase III AEGEAN study evaluating the addition of durvalumab to neoadjuvant chemotherapy for resectable NSCLC
  • Efficacy and safety findings from the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for completely resected NSCLC; FDA approval and current role of adjuvant atezolizumab
  • Available data from the Phase III PEARLS/KEYNOTE-091 study of pembrolizumab as adjuvant therapy for Stage IB to IIIA NSCLC
  • Long-term findings from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
  • Efficacy and safety of durvalumab in combination with oleclumab or monalizumab in the randomized Phase II COAST study
  • Key factors in the decision to use anti-PD-1/PD-L1 monotherapy versus combined chemoimmunotherapy versus dual immune checkpoint inhibition for newly diagnosed metastatic NSCLC without a targetable tumor mutation
  • Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab as monotherapy and combined with chemotherapy as first-line treatment for metastatic NSCLC
  • Available data with first-line cemiplimab monotherapy for patients with NSCLC and PD-L1 in ≥50% of tumor cells
  • Results from the Phase III EMPOWER-Lung 3 study of cemiplimab in combination with platinum-based chemotherapy as first-line therapy for NSCLC
  • Phase III clinical trial results with first-line nivolumab/ipilimumab with and without chemotherapy (CheckMate 227, CheckMate 9LA)
  • Key findings from the Phase III POSEIDON trial evaluating durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy as first-line therapy for metastatic NSCLC
  • Datopotamab deruxtecan for progressive metastatic disease: Mechanism of action, available data and ongoing investigation

Module 2
Chronic Lymphocytic Leukemia (CLL) and Lymphomas | 8:30 AM – 9:30 AM ET

  • Optimal selection of first-line therapy for patients with CLL requiring treatment; long-term data from Phase III studies assessing ibrutinib- and acalabrutinib-based therapy for treatment-naïve CLL
  • Published results from the Phase III SEQUOIA trial comparing zanubrutinib to bendamustine/rituximab (BR) as first-line therapy for previously untreated CLL
  • Results and clinical implications of the Phase III GLOW trial evaluating first-line ibrutinib in combination with venetoclax
  • Implications for clinical decision-making of the Phase III ELEVATE-RR and ALPINE studies comparing acalabrutinib and zanubrutinib, respectively, to ibrutinib for previously treated CLL
  • Updated results from the BRUIN study evaluating the investigational noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib for relapsed/refractory (R/R) CLL
  • CD19-directed chimeric antigen receptor (CAR) T-cell therapy for R/R CLL: Available data, ongoing investigation and potential clinical role
  • Published results with polatuzumab vedotin-based combination regimens for diffuse large B-cell lymphoma (DLBCL) in the newly diagnosed and R/R settings
  • Results from key studies evaluating CAR T-cell therapy as second-line treatment for DLBCL; recent FDA approval of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel in this setting
  • Clinical and biologic factors in the selection and sequencing of polatuzumab vedotin/BR, tafasitamab/lenalidomide, loncastuximab tesirine and CAR T-cell therapy for patients with R/R DLBCL
  • Recently presented outcomes with glofitamab and epcoritamab for R/R DLBCL; potential clinical roles
  • Phase III data evaluating obinutuzumab in combination with chemotherapy for previously untreated follicular lymphoma (FL)
  • Long-term clinical trial findings with lenalidomide/rituximab for treatment-naïve and R/R FL; current role in clinical practice
  • Principal outcomes from pivotal studies evaluating CAR T-cell therapy for FL (eg, ZUMA-5, ELARA); FDA approvals of axi-cel and tisagenlecleucel in R/R FL and their optimal integration into clinical practice
  • Published findings supporting the FDA breakthrough therapy designation for the CD20 x CD3 bispecific antibody mosunetuzumab for R/R FL; potential role in clinical practice
  • Available research with other bispecific antibodies under development for FL (eg, glofitamab, epcoritamab)
  • Current role of brentuximab vedotin (BV) for advanced classical Hodgkin lymphoma (HL) and for older patients with newly diagnosed HL
  • Early findings with BV combined with chemotherapy for early-stage unfavorable-risk HL
  • Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant
  • Biologic rationale for the investigation of antibody-drug conjugates with alternative targets in HL; key findings from the pivotal Phase II study of camidanlumab tesirine for heavily pretreated HL
  • Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R mantle cell lymphoma (MCL); key factors in the choice of a BTK inhibitor
  • Primary results from the Phase III SHINE study of ibrutinib/BR and maintenance rituximab as first-line treatment for older patients with MCL
  • Efficacy and safety findings from the Phase I/II BRUIN study of pirtobrutinib for R/R MCL
  • Early-phase research with venetoclax alone or combined with other agents
  • Clinical research findings with brexucabtagene autoleucel and optimal integration into current MCL treatment algorithms; ongoing assessment of other CAR T-cell platforms for MCL

Morning Break | 9:30 AM – 10:00 AM ET

Module 3
Prostate and Bladder Cancers | 10:00 AM – 11:00 AM ET

  • Indications for and selection of androgen deprivation therapy (ADT) for patients with prostate cancer
  • Use of abiraterone in combination with ADT for high-risk nonmetastatic prostate cancer; potential clinical role
  • Factors in the selection of enzalutamide, apalutamide or darolutamide for nonmetastatic castration-resistant prostate cancer (CRPC)
  • Considerations influencing the choice of abiraterone, enzalutamide, apalutamide or docetaxel to combine with ADT for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
  • Key findings from the Phase III ARASENS trial of darolutamide in combination with docetaxel and ADT for mHSPC; recent FDA approval and current clinical role
  • Factors in the selection and sequencing of therapy for metastatic CRPC (mCRPC); impact of earlier use of chemotherapy and secondary hormonal therapy
  • Findings from the Phase III VISION study evaluating 177Lu-PSMA-617 for progressive PSMA-positive mCRPC; recent FDA approval and appropriate integration into clinical practice
  • Early results with and ongoing evaluation of 177Lu-PSMA-617 in combination with other systemic therapies
  • Frequency of homologous recombination repair (HRR) gene mutations in prostate cancer; indications for and practical implementation of genetic testing
  • Optimal integration of approved PARP inhibitors into management algorithms for mCRPC
  • Efficacy and safety findings from the Phase III PROpel trial comparing olaparib in combination with abiraterone to abiraterone alone as first-line therapy for patients with mCRPC with and without HRR gene mutations
  • Results of the Phase III MAGNITUDE study of niraparib with abiraterone/prednisone as first-line therapy for patients with mCRPC with and without HRR gene mutations
  • Potential clinical role of PARP inhibitors in combination with secondary hormonal therapy as first-line treatment
  • Identification of appropriate patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for pembrolizumab therapy
  • Results of the Phase III CheckMate 274 trial comparing nivolumab to placebo after surgery for patients with high-risk muscle-invasive bladder cancer (MIBC); FDA approval and optimal integration into routine practice
  • Mechanism of antitumor activity and early data with the novel intravesical drug delivery system TAR-200
  • Ongoing studies of TAR-200 with and without the anti-PD-1 antibody cetrelimab for NMIBC and MIBC
  • Current clinical role of anti-PD-1/PD-L1 antibodies as monotherapy or as maintenance after chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC)
  • Long-term outcomes with enfortumab vedotin for patients with progressive mUBC; appropriate integration into the treatment paradigm
  • Emerging results from cohort K of the EV-103/KEYNOTE-869 study of first-line enfortumab vedotin in combination with pembrolizumab
  • Extended follow-up with erdafitinib for patients with mUBC and FGFR3 or FGFR2 genetic alterations
  • Activity of sacituzumab govitecan for patients with progressive mUBC; optimal incorporation into disease management
  • Spectrum, incidence and severity of toxicities with enfortumab vedotin, erdafitinib or sacituzumab govitecan; mitigation and management strategies
  • Early data with novel HER2-targeted therapies (eg, disitamab vedotin, trastuzumab deruxtecan) for mUBC

Module 4
Renal Cell Carcinoma (RCC) | 11:00 AM – 11:20 AM ET

  • Key data from the Phase III KEYNOTE-564 trial documenting the benefit of adjuvant pembrolizumab for patients with RCC at intermediate-high or high risk of recurrence after nephrectomy
  • Ongoing Phase III studies evaluating immune checkpoint inhibitors as neoadjuvant and/or adjuvant therapy for high-risk RCC; perspectives on the negative Phase III IMmotion010 trial
  • Long-term findings with nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-naïve metastatic RCC (mRCC)
  • FDA approval of nivolumab/cabozantinib for previously untreated mRCC and principal findings from the pivotal Phase III CheckMate 9ER study
  • Key findings from the Phase III CLEAR trial leading to the FDA approval of lenvatinib and pembrolizumab as first-line therapy for mRCC
  • Progression-free survival advantage with nivolumab/ipilimumab/cabozantinib for patients with previously untreated advanced, intermediate- or poor-risk RCC in the COSMIC-313 study
  • Clinical outcomes from the Phase III TIVO-3 trial comparing tivozanib to sorafenib as third- or fourth-line therapy for RCC
  • Mechanism of action of belzutifan; proportion of patients with von Hippel-Lindau-associated RCC and optimal role of belzutifan in this population; emerging data and ongoing studies in mRCC

Module 5
CAR-T and Bispecific Therapy for Multiple Myeloma (MM) | 11:20 AM – 11:40 AM ET

  • Biologic rationale for targeting B-cell maturation antigen (BCMA) in MM
  • Principal results from pivotal studies of FDA-approved BCMA-targeted CAR T-cell therapies for R/R MM (KarMMa, CARTITUDE-1 and 2); optimal timing of therapy, patient selection and key ongoing clinical trials
  • Key data with belantamab mafodotin monotherapy for R/R MM; FDA approval and incorporation into routine practice
  • Early data with and ongoing evaluation of belantamab mafodotin in combination with other systemic therapies and/or in earlier lines of treatment
  • Similarities and differences in the cellular targets, mechanisms of action, emerging data and ongoing clinical trials of bispecific antibodies under clinical development for R/R MM (eg, teclistamab, REGN5458, talquetamab, cevostamab)
  • Spectrum, incidence and severity of toxicities with belantamab mafodotin, CAR T-cell therapy and bispecific antibodies in patients with MM; mitigation and management protocols

Module 6
Hepatobiliary Cancers | 11:40 AM – 12:00 PM ET

  • Long-term data from the Phase III IMbrave150 study establishing the benefit of first-line atezolizumab/bevacizumab for patients with unresectable hepatocellular carcinoma (HCC)
  • FDA priority review status and potential clinical role of durvalumab/tremelimumab based on results from the Phase III HIMALAYA trial evaluating that combination or durvalumab alone as first-line treatment for unresectable advanced HCC
  • Implications of emerging results from the Phase III LEAP-002 trial evaluating lenvatinib with and without pembrolizumab as first-line treatment for advanced HCC
  • Recent FDA approval of durvalumab in addition to first-line gemcitabine/cisplatin for patients with advanced biliary tract cancers; principal findings from the pivotal Phase III TOPAZ-1 trial
  • Key data leading to the FDA approvals of pemigatinib and infigratinib for previously treated FGFR-altered locally advanced or metastatic cholangiocarcinoma; optimal integration into clinical practice
  • Available data with, FDA priority review status for and potential clinical role of the FGFR inhibitor futibatinib for previously treated cholangiocarcinoma
  • Other available and investigational treatment strategies (eg, ivosidenib, trastuzumab deruxtecan) for advanced cholangiocarcinoma and other biliary tract cancers

Noon Break and Lunch Buffet | 12:00 PM – 2:00 PM ET

Module 7
Breast Cancer | 2:00 PM – 3:00 PM ET

  • Clinical factors in the selection and sequencing of therapy for patients with HER2-positive metastatic breast cancer (mBC)
  • Recent FDA approval of trastuzumab deruxtecan (T-DXd) as second-line therapy and key findings from the pivotal Phase III DESTINY-Breast03 study for previously treated HER2-positive mBC
  • Long-term results, including final overall survival (OS) data, from the HER2CLIMB study of tucatinib/trastuzumab/capecitabine for HER2-positive mBC
  • CNS activity observed with tucatinib/trastuzumab/capecitabine and with T-DXd in the pivotal studies leading to their approvals and further research (eg,TUXEDO-1 trial) for patients with brain metastases
  • Recent FDA approval of T-DXd for previously treated HER2-low mBC and key efficacy and safety results from the pivotal Phase III DESTINY-Breast04 study; implications for routine clinical practice and the ongoing DESTINY-Breast06 study
  • Spectrum, frequency and severity of toxicities associated with approved HER2-targeted agents for mBC; recommendations for monitoring, prevention and management
  • Major findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative localized breast cancer, 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® (RS) of ≤25
  • Other recent clinical studies informing the use of the 21-gene RS to guide neoadjuvant and adjuvant treatment decision-making
  • Key outcomes observed with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk for recurrence in the Phase III monarchE trial; identification of appropriate candidates for this strategy
  • Findings with olaparib as adjuvant therapy for patients with ER-positive breast cancer with BRCA mutations in the Phase III OlympiA study; current role of adjuvant olaparib
  • Long-term follow-up, including OS findings, from pivotal clinical trials of the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib for ER-positive mBC; available data with CDK4/6 rechallenge (eg, from the MAINTAIN study)
  • OS benefit with and tolerability of sacituzumab govitecan versus chemotherapy of physician’s choice for patients with heavily pretreated ER-positive, HER2-negative mBC in the Phase III TROPiCS-02 study
  • Major findings from the pivotal Phase III KEYNOTE-522 study demonstrating an event-free survival advantage with neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized triple-negative breast cancer (TNBC); FDA approval of (neo)adjuvant pembrolizumab, patient selection and practical implementation in the clinic
  • Key data, including OS outcomes, from the Phase III OlympiA trial assessing adjuvant olaparib versus placebo for patients with high-risk HER2-negative breast cancer and germline BRCA1/2 mutations
  • Principal clinical research findings guiding the use of immune checkpoint inhibitors and PARP inhibitors for metastatic TNBC
  • FDA approval of sacituzumab govitecan for patients with locally advanced or metastatic TNBC who received 2 or more prior systemic therapies; key efficacy and safety results from the pivotal Phase III ASCENT trial, incorporation of sacituzumab govitecan into the clinical treatment algorithm and ongoing studies in earlier-stage disease (SASCIA, ASCENT-03, ASCENT-04)

Module 8
Endometrial Cancer (EC) | 3:00 PM – 3:20 PM ET

  • Clinical relevance of molecular classification in EC and the incidence of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) advanced disease
  • Longer-term data with dostarlimab or pembrolizumab monotherapy for MSI-H/dMMR advanced EC; likelihood, rapidity and durability of response
  • Biologic rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
  • FDA approval of lenvatinib/pembrolizumab and major findings from the Phase III KEYNOTE-775 trial comparing that combination to chemotherapy for advanced EC previously treated with a platinum-based regimen
  • Scientific justification for and design of the ongoing Phase III LEAP-001 trial evaluating lenvatinib/pembrolizumab versus platinum-based chemotherapy as first-line treatment for advanced EC
  • Ongoing Phase III trials evaluating paclitaxel/carboplatin with or without anti-PD-1/PD-L1 antibody therapy for recurrent or primary advanced EC (eg, RUBY, AtTEND, DUO-E)
  • Mechanism of action of selinexor and the biologic rationale for its use in EC; early-phase data and key findings from the Phase III SIENDO trial evaluating selinexor versus placebo as maintenance therapy after first-line chemotherapy for advanced EC

Afternoon Break | 3:20 PM – 3:50 PM ET

Module 9
Ovarian Cancer (OC) and PARP Inhibitors | 3:50 PM – 4:10 PM ET

  • Key outcomes from Phase III studies (eg, SOLO-1, PRIMA, PRIME, PAOLA-1) supporting maintenance therapy with olaparib, niraparib and olaparib/bevacizumab for newly diagnosed advanced OC
  • Results from the Phase III ATHENA-MONO study assessing rucaparib as first-line maintenance therapy; impact of recent FDA actions on the developmental timeline for this strategy
  • Findings from the Phase II OVARIO study assessing maintenance with niraparib/bevacizumab after front-line platinum-based chemotherapy/bevacizumab for advanced OC
  • Long-term follow-up from pivotal trials evaluating niraparib, olaparib and rucaparib for platinum-sensitive and platinum-resistant recurrent OC; rationale for the voluntary withdrawal of the FDA indication for rucaparib of OC with BRCA mutation after at least 2 prior lines of chemotherapy
  • Key findings from the Phase IIIb OReO study evaluating PARP inhibitor rechallenge in patients who have experienced disease progression on or after PARP inhibitor therapy
  • Results from early-phase studies (eg, MEDIOLA, TOPACIO, OPAL, MOONSTONE) evaluating PARP inhibitors in combination with anti-PD-1/PD-L1 antibodies with or without bevacizumab for OC; ongoing Phase III clinical trials (eg, ATHENA-COMBO, FIRST, DUO-O)

Module 10
Gastrointestinal Cancers | 4:10 PM – 5:10 PM ET

  • Rationale for and available data with longitudinal circulating tumor DNA/minimal residual disease measurement in localized colorectal cancer (CRC); clinical utility in treatment decision-making and monitoring for recurrence
  • Recently presented results from the Phase III PARADIGM trial and implications for the use of EGFR antibody therapy as a component of first-line treatment
  • Appropriate integration of encorafenib/cetuximab into clinical practice for patients with BRAF V600E-mutant metastatic CRC (mCRC); early findings with and ongoing evaluation of first-line BRAF-targeted therapy
  • Updated data from the Phase II DESTINY-CRC01 study of T-DXd for patients with HER2-expressing mCRC
  • Recently presented findings from the pivotal Phase II MOUNTAINEER trial evaluating tucatinib/trastuzumab for previously treated HER2-positive mCRC
  • Key data with immune checkpoint inhibitors for MSI-H/dMMR mCRC (pembrolizumab in the KEYNOTE-177 trial and nivolumab/ipilimumab in the CheckMate 142 trial); role in patient care
  • Incidence of KRAS G12C mutations in patients with mCRC; early results with and ongoing evaluation of KRAS G12C inhibitors (eg, sotorasib, adagrasib)
  • Published outcomes from the Phase III CheckMate 577 study of adjuvant nivolumab for resected esophageal or gastroesophageal junction (GEJ) cancer; selection of patients for adjuvant nivolumab
  • Phase III data sets (eg, from the CheckMate 649, CheckMate 648 and KEYNOTE-590 trials) demonstrating the efficacy and safety of first-line checkpoint inhibitor-containing regimens for advanced gastric, GEJ and esophageal cancer; practical and evidence-based incorporation into clinical practice
  • Principal outcomes from the Phase III KEYNOTE-811 trial supporting the first-line use of pembrolizumab/trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
  • Published efficacy and safety data from the DESTINY-Gastric01 and DESTINY-Gastric02 trials of T-DXd for progressive HER2-positive gastric/GEJ cancer
  • Frequency of FGFR2b overexpression in gastroesophageal cancers; mechanism of action of bemarituzumab
  • Major efficacy and safety data with and ongoing evaluation of first-line bemarituzumab/chemotherapy for FGFR2b-positive metastatic gastric/GEJ cancer
  • Frequency of germline BRCA mutations and other DNA damage repair alterations in pancreatic adenocarcinoma (PAD); indications for and practical implementation of genetic testing
  • Long-term findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD with a germline BRCA mutation

Module 11
Melanoma | 5:10 PM – 5:30 PM ET

  • Long-term results from the Phase III COMBI-AD study evaluating dabrafenib/trametinib as adjuvant treatment for high-risk BRAF V600-mutant melanoma
  • Efficacy and safety of adjuvant anti-PD-1 antibody therapy for patients with Stage III or IV melanoma
  • Use of pembrolizumab as adjuvant treatment for patients with surgically resected, high-risk Stage II melanoma
  • Factors in the decision to administer nivolumab, pembrolizumab or dabrafenib/trametinib as adjuvant treatment
  • Key findings from the Phase III DREAMseq trial evaluating the optimal sequence of therapies for BRAF-mutant metastatic melanoma
  • Recent FDA approval, based on the RELATIVITY-047 trial, of relatlimab/nivolumab for previously untreated metastatic or unresectable melanoma
  • Activity and tolerability of the anti-LAG-3 monoclonal antibody fianlimab combined with cemiplimab in patients with advanced melanoma; ongoing Phase III evaluation
  • Findings from the LEAP-004 study evaluating lenvatinib/pembrolizumab for previously treated metastatic melanoma; ongoing Phase III evaluation of this combination as first-line therapy
  • Activity of the autologous tumor-infiltrating lymphocyte therapy lifileucel for advanced melanoma; FDA RMAT (regenerative medicine advanced therapy) designation, development plans and potential clinical role

MEETING ADJOURNS | 5:30 PM ET

* Meal service will be provided for onsite program attendees.

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, hepatobiliary cancers, lung cancer, melanoma and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing clinical trials in breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, hepatobiliary cancers, lung cancer, melanoma and select hematologic cancers, and refer appropriate patients for participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in individualizing therapy for patients with cancer.
  • Educate patients with hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms, considering new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCPD Credit Designation Statements
This educational activity for 7 contact hours is provided by Research To Practice.

This activity is awarded 7 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, please complete an Educational Assessment and Credit Form with your participation hours. Please note, MOC and ONCC credit instructions will be emailed to participants within 3 to 5 business days of the program.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 7 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Abou-AlfaConsulting Agreements: Adicet Bio, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, BeiGene Ltd, Berry Genomics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Servier Pharmaceuticals LLC, Silenseed Ltd, Sobi, Vector Pharma, Yiviva; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Group, Puma Biotechnology Inc, QED Therapeutics, Silenseed Ltd, Yiviva. Dr GoetzAdvisory Committee: ARC Therapeutics, bioTheranostics Inc, Blueprint Medicines, Sanofi Genzyme; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biovica, Context Therapeutics, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc; Contracted Research: Lilly, Pfizer Inc, Sermonix Pharmaceuticals; Nonrelevant Financial Relationship (CME Presentation Fees): Clinical Education Alliance, Medscape, MJH Life Sciences; Nonrelevant Financial Relationship (Panelist): Total Health Conferencing. Dr KropConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc, Taiho Oncology Inc; Contracted Research (Clinical Trial Support Paid to Institution): Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc. Dr LaCasceAdvisory Committee: Seagen Inc. Dr LangerAdvisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Lilly, Merck, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Lilly, Merck, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Advantagene Inc, Amgen Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc, Trizell; Data and Safety Monitoring Board/Committee: OncocyteRx; Nonrelevant Financial Relationship: US Department of Veterans Affairs. Prof LongConsulting Agreements: Agenus Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Evaxion Biotech A/S, Hexal AG, Highlight Therapeutics SL, Innovent USA, Merck Sharp & Dohme LLC, Novartis, OncoSec Medical, PHMR, Pierre Fabre, Provectus Biopharmaceuticals Inc, QBiotics, Regeneron Pharmaceuticals Inc. Dr MessersmithConsulting Agreements: Cardiff Oncology, Istari Oncology; Contracted Research: ALX Oncology, AStar EDCC, BeiGene Ltd, CanBas Co Ltd, Exelixis Inc, Fate Therapeutics, Pfizer Inc, PureTech Health, Mirati Therapeutics, Rascal Therapeutics; Data and Safety Monitoring Board/Committee: Amgen Inc, QED Therapeutics, Zymeworks Inc; Unpaid Advisory Board: Pfizer Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Criterium. Dr MorgansAdvisory Committee: Bayer HealthCare Pharmaceuticals, Gilead Sciences Inc, MyovantSciences; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme, Telix Pharmaceuticals; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Myovant Sciences, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc. Dr O'MalleyFunding for Clinical Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, ArrayBioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Mersana Therapeutics Inc, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Sumitomo Dainippon Pharma Oncology Inc, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc; Personal Fees (Consulting and/or Advisory Boards): AbbVie Inc, Ambry Genetics, Amgen Inc, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Celsion Corporation, Clovis Oncology, Corcept Therapeutics, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Diagnostics MSA, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Toray; Personal Fees: Agenus Inc, Myriad Genetic Laboratories Inc, Rubis, Tarveda Therapeutics; Nonrelevant Financial Relationship: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, Yale University. Dr PowlesConsulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc; Nonrelevant Financial Relationship: Mashup Media LLC. Dr SmithAdvisory Committee: Janssen Biotech Inc; Speakers Bureau: Acrotech Biopharma. Dr StricklerAdvisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Inivata, Natera Inc, Pfizer Inc, Seagen Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Viatris; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Pionyr Immunotherapeutics, Seagen Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Amgen Inc, AStar D3, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Lilly, Nektar, Sanofi Genzyme, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, Pionyr Immunotherapeutics. Dr UsmaniConsulting Agreements: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Oncopeptides, Sanofi Genzyme, Seagen Inc, Secura Bio, SkylineDX, Takeda Pharmaceuticals USA Inc, TeneoBio; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seagen Inc, SkylineDX, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Sanofi Genzyme. Dr WestinConsulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Bio, Nuvectis Pharma Inc, Seagen Inc, Vincerx Pharma, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bio-Path Holdings, Clovis Oncology,Genentech, a member of the Roche Group, GlaxoSmithKline, Mereo BioPharma, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals. Dr YuAdvisory Committee: Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Oncternal Therapeutics; Consulting Agreements: Exelixis Inc, Merck; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Seagen Inc, Taiho Oncology Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Merck, Natera Inc, Novartis, Regeneron Pharmaceuticals Inc, and Seagen Inc.

JW Marriott Orlando, Grande Lakes
4040 Central Florida Parkway
Orlando, FL 32837
Hotel Phone: (407) 206-2300

Meeting Room
Coquina Ballroom – Lobby Level

Hotel Accommodation
If you are a Florida Cancer Specialist (FCS) or approved FCS vendor, please contact FCS to secure your hotel accommodation.

For all other in-person attendees, at this time the group housing block is full. To secure accommodations, please contact the JW Marriott Orlando, Grande Lakes hotel directly, toll free (800) 266-9432 or (407) 206-2300. The hotel will offer their best current rate based on availability at either the JW Marriott Orlando, Grande Lakes hotel or its connected sister property, the Ritz-Carlton Orlando, Grande Lakes hotel.

Directions:
The JW Marriott Orlando, Grande Lakes is the main venue for the 2022 Florida Cancer Specialists Clinical Summit.

 
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited for the in-person meeting in Orlando.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
​ ​
IN-PERSON StandBy registration for other/industry professionals*

Thank you for your interest. We will inform you if your in-person registration request has been approved.

IN-PERSON StandBy Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering for the webcast, you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

​ Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

​ Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.